Proactive Investors - Run By Investors For Investors

Itaconix CEO on significance of recent deal with chemical firm Nouryon

John R. Shaw, chief executive of Itaconix Plc (LON:ITX), caught up with Proactive's Andrew Scott while in London to update on the  exclusive supply agreement they signed in February with chemical firm Nouryon for its bio-based polymers.

Under the agreement, Itaconix will supply its polymers to Nouryon who will then market them to its customers in personal care products such as sunscreen, body wash, and cosmetics.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full ITX profile View Profile

Itaconix Plc Timeline

CN Research
March 21 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use